AzTrials
AzTrials

Thyroid Gland; NodeNCT02378233

Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant

A study testing iodine in people with Thyroid Gland; Node and Lactation, run by Göteborg University at 1 site in Sweden.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The aim of the study is to measure urinary milk iodine concentration (MIC), iodine concentration (UIC), thyroid hormones (TSH, FT4) and thyroperoxidase antibodies (TPOab) in breast-feeding women, and UIC in their nursing infants to determine if the levels are adequate, and to see how they can be influenced by 150 ug… Read more about this study

Who is it for?
Ages 18 to 40 years, women only
Conditions the study is for
Thyroid Gland; Node, Lactation
What is being tested?
iodine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
77 participants
Where
1 siteSweden
Study dates
Oct 2011to 5 Mar 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • 18-40 years.
  • Pregnancy longer than week 36.
  • Single Pregnancy.
  • Planned breastfeeding.
  • No current thyroid disease.
  • Agree not to take iodine supplementation except as provided through the study.
Show all 9Show fewer
  • 18-40 years.
  • No current thyroid disease.
  • Agree not to iodine supplementation during the study.

Who cannot join

  • Patient who is not expected to adhere to the research protocol. Plans for pregnancy within 6 months after delivery.
  • Vegans.
  • CONTROL WOMAN:
  • Patient who is not expected to adhere to the research protocol.
  • Plans for pregnancy within 6 months of study entry.
  • Vegans.

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Health Care center

    Mölnlycke, SE-435 30

Other trials in Sweden

About this study

Official title: A Double-blinded Randomised Study of Iodine Supplementation to Lactating Women in an Iodine-sufficient Area in Sweden and Evaluation of Maternal and Neonatal Iodine Levels and Thyroid Function

The aim of the study is to measure urinary milk iodine concentration (MIC), iodine concentration (UIC), thyroid hormones (TSH, FT4) and thyroperoxidase antibodies (TPOab) in breast-feeding women, and UIC in their nursing infants to determine if the levels are adequate, and to see how they can be influenced by 150 ug daily iodine supplementation in breast-feeding women. The hypothesis is that there is a relative iodine deficiency in this sub-population - lactating women and nursing children-, and that this can be influenced by iodine supplementation. Adequate thyroid hormone and iodine levels are very important for small children, when the plasticity of the brain is greatest.

This is as a prospective, double-blind, placebo-controlled study of 221 mothers and their infants. In parallel, 90 age-matched healthy non-pregnant women are recruited. Mothers are randomized to 150 µg/day iodide supplementation or placebo.

Pregnant women are asked for participation on a visit in pregnancy week 37, at the mother health care (MVC) at Mölnlycke and Skövde. The study will run for approximately 3 months for each individual and begins by sampling A (UIC, TSH, FT4, TPOab) at week 37 of the pregnancy, when mothers also get randomized to 150 µg iodine or placebo. New sampling B (UIC, TSH, FT4, MIC ) is collected when the baby is 3 months old. Thereafter the study is completed. In parallel, 90 healthy non-pregnant, non-lactating women in the same age range are recruited and followed with UIC, TSH, FT4, TPOab for 6 months as a control group. In each case a simple questionnaire is filled and blood is also frozen for future analyses.

Read the detailed description

Are the mothers to be treated with 150 µg iodide per day during lactation to guarantee normal intake of iodine in breast-milk (MIC) and normal urinary iodine concentration (UIC) in their off-spring?

Purpose and Aim This prospective, placebo-controlled study focus on the question whether lactating mothers shall add 150 µg iodide po to guarantee normal MIC and UIC levels in their children or not, as current iodinating program does not guarantee normal levels in these subgroups

  • Primary aim: To compare the MIC and UIC of the children to lactating mothers receiving 150 µg iodide or receiving placebo and compare to WHO recommendations.
  • Secondary aim: To study UIC in the mothers during lactation compared to controls.

To study the frequency of thyroid dysfunction in lactating women and whether it differs among patients on 150 µg or placebo.

If the UIC concentration in the children breast fed by mothers receiving placebo is lower than the recommended levels by the WHO and if these levels are normalized with 150 µg iodide to the mother this study will be the supportive study for national authorities in Sweden, Europe and in the world to recommend all lactating mothers to add 150 µg when breast feeding even if the country is judged iodine sufficient.

Survey of the field Iodine deficiency in the nature affects thyroid function The supply of iodine varies in different parts of the world, mainly because of varying levels of iodine in the ground water, different soils and plants, different distribution of sea-food, and dissimilar diary food consumption. In many areas with depleted soils and a long distance to the sea, iodine deficiency (ID) is still a major health problem.

Adequate dietary iodine intake is essential for the production of thyroid hormones. Low iodine intake results in the development of hypothyroidism and goiter. Impaired production of thyroid hormones during pregnancy affects growth and brain development in the progeny. Iodine deficiency in school-age children impairs somatic growth, cognitive performance and motor function.

Iodine insufficiency outside Sweden Iodine deficiency remains a public health problem in 47 countries worldwide. Although most countries worldwide have implemented universal salt iodization , countries like Australia, New Zealand and several European countries have been reporting reoccurring iodine deficiency. Changes in food consumption patterns, legislation not covering processed food and decreased salt consumption impose new challenges in ensuring adequate iodine nutrition in the population.

Iodine sufficiency in Sweden In Sweden, goitre was first described by Carl von Linné in 1747, and in the beginning of the 20th century, goitre was detected in 60% of cases in certain areas (19) and in 18% of the total population . A national survey conducted in 1929 confirmed endemic goitre regions located in the inner or eastern part of the country: these iodine deficient areas were known as the "goitre-belt".

These observations contributed to initiation of the Swedish national iodine fortification program for salt in 1936. Initially, 10 mg of potassium iodide (KI) was added to every kilogram salt. In 1966, this was increased to the current level of 50 mg/kg salt, as goitre was still prevalent in some regions of the country.

The first national evaluation of iodine status in Sweden was performed by our group according to the recommendations of the World Health Organization (WHO). Urinary iodine concentration (UIC) was measured in a representative national sample of children aged 6-12 years: the national median UIC was 125 μg/L, indicating optimal iodine nutrition . However, thyroid volumes were higher in Swedish school children than in the international reference study, which may be an effect from genetic and other environmental factors. Iodine intake is considered optimal in Sweden. These findings underline the importance of regular monitoring of iodine intake, especially concerning the decreased intake of table salt that is likely to follow health campaigns and patients with higher need of iodine may be at risk.

Iodine demands increase during pregnancy and lactating The need of iodine is increased during pregnancy and lactating because of the increased thyroid hormone production and enrichment of iodine in breast-milk. An intake of iodide during pregnancy and breast feeding of 250 µg is recommended compared to 150 µg/day in the normal population. Severe iodine deficiency in the new-borne results in cretinism.

The most critical period except for the prenatal period for the child is the two first years of life when the brain still develops. An enhanced risk period is the first 6 month of life when the child is breast-feeding. During this period the child is depending on the iodine concentration in the milk, which is a direct consequence of the mother iodine nutrition. When the infant starts to eat, iodide is supplied from the food.

Numerous studies have measured both thyroid hormones and MIC in women living in iodine sufficient and insufficient regions, which are summarized in three reviews . Three studies have evaluated iodine nutrition in infants longitudinally , whereas the most recent from New Zealand is the longest; during 6 months maternal and infant iodine status were measured.

In the world and the communities of thyroid disease the question is debated whether or not iodide shall be given to pregnant women. American thyroid Association (ATA) has made a strong recommendation for this in fear the even mild iodine deficiency in small children may affect the brain development negatively. WHO has modified their guidelines of supplementation to whether the nation is regarded iodine sufficient, including sufficient levels in pregnant and lactating women (category 1), where no iodide supplementation is need, or not sufficient. The latter group is divided in two; one group where most patient, but <90%, eat iodinated salt and UIC <100 (category 2) and one group with similarly low UIC but where iodized salt is scarcely used (category 3). An iodine supplement of 150 µg is the recommendation in these countries. However, in 2010 Mulrine et al performed a placebo controlled study the first 6 months postpartum. The mothers were iodine deficient, as New Zealand had not implemented an iodizing program, and were supplemented with 75 or 150 µg/day. Both mother and child had UIC and MIC lower than recommend by the WHO. The authors encourage a study done in the circumstances of iodine sufficiency in the nation.

Data from pregnant and lactating women in Sweden are scares. Two small local studies reports median UIC 145-178 µg/dag and 89 µg/l during pregnancy. More knowledge is needed to judge if Swedish woman shall have and iodine supplementation of 150 µg/day or not during this vulnerable period of life for their children.

Project description Study design This is a prospective, double-blinded placebo-controlled trial of 221 lactating women and their children. Mothers are randomized to 150 µg/day iodine supplementation or placebo for 15 weeks. In parallel 90 healthy female controls are recruited from the same community stratified for age and smoking habits. Patients are included after week 36 in pregnancy by the midwife and urinary iodine concentration (UIC), thyroid hormones levels and thyroperoxidase antibodies (TPO-ab) are assessed and a simple questionnaire is filled in by the pregnant women. Placebo/iodine is started at the same visit (allocation 1:1). At the visit 13 (13±1) weeks postpartum UIC, thyroid hormones levels and thyroperoxidase antibodies (TPO-ab) are assessed in all mothers and a simple questionnaire is filled in. MIC is measured in those who still breast-feed. UIC is measured in babies. At all occasion blood specimens are taken, blood is also frozen for future analyses. Weight and length are registered postnatal in the child.

Study population Patients At the antenatal care unit at Mölnlycke and Skövde Health Care center 221 pregnant women aged 18-40 years will be collected consecutively according to inclusion and exclusion criteria.

Inclusion criteria: Pregnant ≥36 weeks, Singleton pregnancy, Aged 18-40 years, Intend to breast-feed, Agree to take no iodine containing supplements during the study postpartum except for study medication, No current thyroid disease Exclusion criteria: Patient who may not attend to the protocol according to the investiga¬tor's opinion, Plans of another pregnancy within the first 6 months postpartum, Vegans

Controls Controls are collected from a randomized sample attain by the Swedish Tax Agency of premenopausal women from Mölnlycke community. Controls in the same age as the patients are contacted by mail for participation in the study and if smoking habits agree with the corresponding patient they come for an inclusion visit. If interested, the controls are told to stop any other iodine containing supplements 1 week before the first visit. If no answer, a reminding letter is sent after two weeks.

Inclusion criteria: Aged 18-40 years, Agree to take no iodine containing supplements during the study postpartum. No current thyroid disease Exclusion criteria: Controls who may not attend to the protocol according to the investiga¬tor's opinion, Plans pregnancy within the next 6 months, Vegans

Significance If the study proves that supplement of 150 µg iodine to mothers guarantee normal iodine intake in the newborn child contact will be taken with the National Food Agency, the National Board Health and Social welfare and the government to lobbying for a general directives of iodine supplementation to all lactating women.

Being tested
iodine, Placebo
Keywords
Iodine, Double-Blind Method, Randomized Controlled Trial
Medical subject headings
Thyroid Diseases, Breast Feeding

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • iodineDietary supplement

    The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.

  • PlaceboDietary supplement

    Patients are given a non-iodine containing multivitamin tablet

Study groups in NCT02378233
Study groupRoleWhat they receive
iodineExperimentaliodine containing multivitamin 150 ug, 1 tablet daily
Receives: Dietary Supplement: iodine
placeboPlacebo comparatorplacebo, 1 tablet Daily of a non-iodine containing multivitamin
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. milk iodine concentration

    Measured: 3 months after birth (within 7 days)

  2. urinary iodine concentration in the infant

    Measured: 3 months after birth (within 7 days)

Secondary outcomes (8)
  1. TSH in the mother

    Measured: pregnancy week 37

  2. TSH in the mother

    Measured: 3 months after birth

  3. FT4 in the mother

    Measured: pregnancy week 37

  4. FT4 in the mother

    Measured: 3 months after birth

  5. TPOab in the mother

    Measured: pregnancy week 37

  6. TPOab in the mother

    Measured: 3 months after birth

  7. urinary iodine concentration in the mother

    Measured: pregnancy week 37

  8. urinary iodine concentration in the mother

    Measured: 3 months after birth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2015 (estimated)
  2. Study startOct 2011
  3. Primary completionDec 2017
  4. Study completion5 Mar 2024

Why it stopped: Fail to complete the recruitment due to lacking resources

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
77 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02378233
Sponsor's protocol ID
12012002
Status last verified
Mar 2024
First submitted
19 Jan 2015
Last updated
15 Mar 2024
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing iodine in people with Thyroid Gland; Node and Lactation, run by Göteborg University at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 15 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Fail to complete the recruitment due to lacking resources). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

milk iodine concentration (time frame: 3 months after birth (within 7 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in